Meridian Bioscience (VIVO +27.5%) is up on average volume in reaction to its announcement that
diagnostic companies and laboratories in China are using its Lyo-Ready
1-Step RT-qPCR Mix to develop screening tests for the 2019-nCoV
coronavirus causing the current outbreak of respiratory illnesses.
https://seekingalpha.com/news/3534704-meridian-bioscience-joins-coronavirus-rally-up-28
Monday, January 27, 2020
Trovagene up on positive onvansertib data
Nano cap Trovagene (NASDAQ:TROV) jumps 20% premarket on robust volume in reaction to encouraging preliminary data from a Phase 1b/2 clinical trial
evaluating lead drug onvansertib, combined with chemo regimen FOLFIRI
and Roche’s Avastin (bevacizumab), for the second-line treatment of KRAS
mutation-positive metastatic colorectal cancer. The results were
presented at the ASCO GI Cancers Symposium in San Francisco.
Tumor regression was observed across all major
KRAS mutation types, including three patients experiencing at least 25%
tumor shrinkage. One patient is proceeding to curative surgery.
https://seekingalpha.com/news/3534676-trovagene-up-20-premarket-on-positive-onvansertib-dataHealthcare dominates premarket gainers as Coronavirus gains
Lianluo Smart (NASDAQ:LLIT) +94%.
Cleveland BioLabs (NASDAQ:CBLI) +55%.
Allied Healthcare Products (NASDAQ:AHPI) +30% Coronavirus-related stocks upagain as contagion spreads.
Vir Biotechnology (NASDAQ:VIR) +15%.
Akari Therapeutics, Plc (NASDAQ:AKTX) +7% on announcing
preclinical ophthalmic data showing Nomacopan reduces both vascular
endothelial growth factor and retinal inflammation supporting Nomacopan
as a potential treatment option for back-of-the-eye diseases.
Trinity Biotech plc (NASDAQ:TRIB) +5%.
https://seekingalpha.com/news/3534681-healthcare-dominates-premarket-gainers-coronavirus-gainEvolus’ Jeuveau matches Botox in study
Evolus (NASDAQ:EOLS) is up 3% premarket on light volume in reaction to its announcement of results from a Korea-based Phase 3 head-to-head study comparing Jeuveau (prabotulinumtoxinA-xvfs) to Allergan’s (NYSE:AGN) Botox (onabotulinumtoxinA) for the treatment of frown lines. The data were just published in the journal Dermatologic Surgery.
The study met the primary endpoint demonstrating
the non-inferiority of prabotulinumtoxinA to onabotulinumtoxinA as
measured by the proportion of patients with Grade 0 or 1 severity of
crow’s feet at maximum smile at week 4.
The FDA approved Jeuveau about a year ago.
Related ticker: AbbVie (NYSE:ABBV)
https://seekingalpha.com/news/3534687-evolus-jeuveau-matches-botox-in-study-shares-up-3-premarketAbbVie donates $1M+ of HIV drug China now recommends for coronavirus
AbbVie is donating more than $1 million worth of an HIV drug to help
combat the fast-spreading coronavirus outbreak in China, the company
announced on Friday.
China’s National Health Commission has suggested Aluvia, a pill containing lopinavir and ritonavir, as one of two possible treatments for the symptoms of the virus currently known as 2019-nCoV in the absence of effective antiviral medications. The other part is nebulized alpha-interferon.
Government officials are rushing to contain and find solutions for an epidemic that originated in the inland city of Wuhan, Hubei but has since popped up in every other region except for Tibet. The Aluvia regimen — two pills per round, twice daily — was included in the third test version of the “diagnosis and treatment plan for new coronavirus infections.”
Guangfa Wang, a Beijing-based pulmonary expert who contracted the virus after visiting Wuhan for an investigation, told China’s Time-Weekly that he took Aluvia as part of his treatment and it appeared to be effective in his case. Shanghai officials said they have adopted this type of HIV drugs since their first patient.
“So far it seems to have certain effects, but we need more clinical observation,” said Hongzhou Lu of the Shanghai Public Health Clinical Center.
The theory, yet to be proven, is that Aluvia works by blocking a protease that the coronavirus needs for reproduction in the human body. Though it’s not the same protease that the drug was originally designed to block, it might be similar enough to delay disease progression. Because of that, Aluvia had previously also been tested in patients with SARS and MERS.
An anonymous Wuhan doctor interviewed by Time-Weekly said that Aluvia is useful against the novel coronavirus, but it’s “hard to come by.”
AbbVie said on WeChat that it will donate RMB$10 million (around $1.44 million) worth of pills in response to the guidance, though it didn’t specify how it would distribute across the country.
Other drugmakers are also rushing to the call for effective medications. Gilead dusted off remdesivir, an antiviral that missed the mark on Ebola, to see about its potential against the new virus. Moderna is allied with the NIH to develop a vaccine while George Scangos’ Vir has brought out antibodies. A raft of small-cap biotechs triggered a stock rally over potential vaccine candidates that might take years, if ever, to materialize.
Treatments are urgently needed as the death toll in China rises to 81, five of them outside Hubei province, with almost 3,000 confirmed cases and double that number of suspected cases even as several cities are on lockdown. So far, five 2019-nCoV cases have been detected in the US.
China’s National Health Commission has suggested Aluvia, a pill containing lopinavir and ritonavir, as one of two possible treatments for the symptoms of the virus currently known as 2019-nCoV in the absence of effective antiviral medications. The other part is nebulized alpha-interferon.
Government officials are rushing to contain and find solutions for an epidemic that originated in the inland city of Wuhan, Hubei but has since popped up in every other region except for Tibet. The Aluvia regimen — two pills per round, twice daily — was included in the third test version of the “diagnosis and treatment plan for new coronavirus infections.”
Guangfa Wang, a Beijing-based pulmonary expert who contracted the virus after visiting Wuhan for an investigation, told China’s Time-Weekly that he took Aluvia as part of his treatment and it appeared to be effective in his case. Shanghai officials said they have adopted this type of HIV drugs since their first patient.
“So far it seems to have certain effects, but we need more clinical observation,” said Hongzhou Lu of the Shanghai Public Health Clinical Center.
The theory, yet to be proven, is that Aluvia works by blocking a protease that the coronavirus needs for reproduction in the human body. Though it’s not the same protease that the drug was originally designed to block, it might be similar enough to delay disease progression. Because of that, Aluvia had previously also been tested in patients with SARS and MERS.
An anonymous Wuhan doctor interviewed by Time-Weekly said that Aluvia is useful against the novel coronavirus, but it’s “hard to come by.”
AbbVie said on WeChat that it will donate RMB$10 million (around $1.44 million) worth of pills in response to the guidance, though it didn’t specify how it would distribute across the country.
Other drugmakers are also rushing to the call for effective medications. Gilead dusted off remdesivir, an antiviral that missed the mark on Ebola, to see about its potential against the new virus. Moderna is allied with the NIH to develop a vaccine while George Scangos’ Vir has brought out antibodies. A raft of small-cap biotechs triggered a stock rally over potential vaccine candidates that might take years, if ever, to materialize.
Treatments are urgently needed as the death toll in China rises to 81, five of them outside Hubei province, with almost 3,000 confirmed cases and double that number of suspected cases even as several cities are on lockdown. So far, five 2019-nCoV cases have been detected in the US.
AbbVie donates $1M+ of the HIV drug that China is now recommending for coronavirus treatment
Sorrento slips 6% premarket on rejection of second takeover bid
The board of Sorrento Therapeutics (NASDAQ:SRNE) has rejected a $7/share bid from a private equity fund saying it “significantly undervalues” the company. It received the offer several weeks ago.
In November 2019, it rebuffed a lower bid from two unnamed biopharma companies.
Shares down 6% premarket on average volume.
https://seekingalpha.com/news/3534617-sorrento-slips-6-premarket-on-rejection-of-second-takeover-bidAnalyst action, Jan. 27
Relmada Therapeutics (NASDAQ:RLMD) initiated with Buy rating and $75 (73% upside) price target at Jefferies.
Biogen (NASDAQ:BIIB)
upgraded to Buy with a $360 (29% upside) price target at Canaccord
Genuity citing the potential FDA nod for aducanumab in Alzheimer’s.
Shares down 1% premarket.
Denali Therapeutics (NASDAQ:DNLI) upgraded to Buy with a $37 (50% upside) price target at Goldman Sachs. Shares up 1% premarket.
Intuitive Surgical (NASDAQ:ISRG) downgraded to Hold at Deutsche Bank. Shares down 3% premarket.
Medpace Holdings (NASDAQ:MEDP) downgraded to Hold with an $87 (1% downside risk) price target at SunTrust.
Mylan N.V. (NASDAQ:MYL) downgraded to Market Perform with a $24 (10% upside) price target at SVB Leerink. Shares down 4% premarket.
Tivity Health (NASDAQ:TVTY) downgraded to Neutral at Piper Sandler.
https://seekingalpha.com/news/3534642-canaccord-likes-biogen-in-premarket-analyst-action
Subscribe to:
Posts (Atom)